Friday, September 3, 2010
"Concise industry news from the US pharmaceutical industry..."
Sponsors
Platinum Sponsors
Nanopoint, Inc.
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
Gold Sponsors
Waters Corp.
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Silver Sponsors
Platinum Sponsors
Nanopoint, Inc.
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
Gold Sponsors
Waters Corp.
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Silver Sponsors
Blog
Where our team of guest writers discuss what they think about the current NGP US Issues.
Peter Duncan
Director of Business Development
Director of Business Development
Can digital pathology save drug development?
Peter Duncan of Definiens discusses the potential of digital pathology.07 Jul 2010
Focus Areas
Cover Stories
Leading Lilly Forward
John Lechleiter, newly appointed CEO of Eli Lilly, addresses Lilly’s stance in the industry and reveals the directions in which he’ll be...
The Importance of Operations
Ken Murtha, Regional Vice President Supply for the Americas for AstraZeneca, talks about operations, supply chain management and counterfeit...
The New Risk Management Paradigm
Jill Robinson and Mary Ellen Turner of the Global Safety Surveillance, Epidemiology, and Labeling Group at Wyeth Research discuss their...
Roundtables
-
Successful KOL Management
Marketers recognize that key opinion leader (KOL) management is a critical component of their professional marketing strategies. But how can you make the most of those...Read more
Vendor Perspectives
-
Performance Validation, LLC Next Generat...
Customer centric focus: Customer focus has been defined as placing the wants and needs of the customer as the central focus of all business practices within the company. By...Read more -
PRF&L (Pocono Rabbit Farm and Laboratory...
Currently there are over hundreds of companies selling catalog antibodies or antibody-related products to those in the scientific research community. Over half of these...Read more
Industry Analysts
-
Ensuring Global Compliance
Ensuring compliance on a global scale can be a daunting prospect. Robert Garnick of Genentech talked to NGP about his company’s approach to meeting this challenge.Read more -
Accelerating Drug Development
New tools in the form of ground-breaking techniques and the latest computer hardware are enabling drug developers to design compounds more quickly and accurately than ever...Read more
Executive Interviews
Making the Most of Your Knowledge
While greater access to data provides an opportunity for most organizations, it also represents a challenge in terms of IT. So how can laboratories ensure they are making the most of the scientific knowledge at their disposal? NGP talks to Pat Mar...
Read more
Making the Best of a Tough Situation
Pharmaceutical companies can find themselves subject to corporate integrity agreements (CIAs) if the government discovers noncompliance of fraud and abuse. NGP asked Jayson Dukes of FTI Consulting what companies can do to help ensure a favorable r...
Read more
The Right Connection
Across the global pharmaceutical industry, companies are waking up to the shortcomings of new drug applications. The cost of research and development (R&D) is rising, while the approval rate of innovative new drugs is declining. Joe Herring, Chair...
Read more
Next Generation Healthcare Summit
25th - 27th October 2010
As healthcare costs continue to rise, health providers around the country feel a sharp sense of urgency in deploying information technology to lower costs, reduce medical errors, enhance outcomes, and spur efficiency in an industry known for legendary inefficiency.
Source: www.ngpharma.com© 2010 GDS Publishing Ltd. All rights reserved.